an Integrated Analysis of Radiologic and Pathological Responses in Patients with Metastatic Renal Cell Carcinoma Who Presented with Primary Renal Tumor in Situ and Received First-Line Nivolumab Plus Ipilimumab Followed by Cytoreductive Nephrectomy